SNTI · Senti Biosciences Holdings, Inc.
$0.35
-0.03 (-9.07%)
At close · Jul 29
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company concluded that substantial doubt continued to exist and that the Company's cash and cash equivalents of $8.9 million as of March 31, 2026, were not sufficient for the Company to continue as a going concern for at least one year from the issuance date of these condensed consolidated financial statements.”View the 10-Q filed May 14, 2026
Market Cap
$11.88M
Shares
31.14M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Timothy Lu | CEO | $930,690 |
| Kanya Rajangam | President, Head of Research and Development and Chief Medical Officer | $627,707 |
| Yvonne Li | CFO | $547,540 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Timothy Lu | CEO | $1,686,498 |
| Kanya Rajangam | President, Head of Research and Development and Chief Medical Officer | $858,770 |
| Deborah Knobelman | CFO | $789,656 |
| Yvonne Li | CFO | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Deborah Knobelman | CFO | $1,103,425 |
| Kanya Rajangam | President, Head of Research and Development and Chief Medical Officer | $840,506 |
| Timothy Lu | CEO | $811,262 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Timothy Lu | CEO | $24,497,522 |